Providers

The tentative approval cannot take effect because a competing product was granted market exclusivity.

Ticiana Leal, MD, associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the latest advances in perioperative non–small cell lung cancer (NSCLC) treatment.

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL).

Payers must continue to assess their prior authorization practices to uphold the goals of clinical quality, safety, and utilization management.

A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential biomarkers for assessing CLL risk.

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS).

An analysis on the state of pharmaceutical drug pricing revealed that, despite rebates, consumers' out-of-pocket costs have grown faster than their insurers' prices.

A comparative analysis investigating time from a drug's approval to insurance reimbursement found that the speed of this process in the US falls behind some European countries.

Despite lacking some data, there is some information on which patients with cancer shouldn’t be recommended cannabis or certain cannabis products, said Marie Parish, PharmD, BCOP, a gastrointestinal oncology pharmacist with Mayo Clinic.

David Thompson, PhD, Queen’s University Belfast, expands on previous research he conducted that calls for cardiovascular health care providers to actively address care inequities evident in practice and policy.

Anna Mueller, MD, and Amir Ahmadi, MD, of Mount Sinai, highlight gaps in risk assessment tools for acute coronary syndrome, calling for more comprehensive screening strategies.

A joint session from the European Society of Cardiology and the World Heart Federation examined the impact of noise, climate change, and air pollution on cardiovascular disease.

Advances in technology have made active surveillance in men with prostate cancer possible and prevented treatment for men who don’t need it, said Matthew Nielsen, MD, FACS, chair, Department of Urology, University of North Carolina School of Medicine.

Twice-yearly inclisiran (Leqvio) monotherapy showed clinically meaningful and statistically significant LDL-C lowering in patients at low or moderate risk of atherosclerotic cardiovascular disease in the V-MONO study.

Mark Bleackley, PhD, Incannex, discusses the notable and surprising observations from the ongoing RePOSA study, and the developmental challenges they have encountered with their cannabinoid pharmacotherapy for patients with obstructive sleep apnea.

Research at the European Society of Cardiology Congress 2024 evaluated lipid-lowering therapy beyond statins alone in patients with high levels of low-density lipoprotein cholesterol.

The disease-modifying treatment landscape has expanded in recent years, but access to the latest approved Duchenne muscular dystrophy (DMD) treatments can be a challenge for patients and providers, Aravindhan Veerapandiyan, MD, a pediatric neuromuscular specialist at Arkansas Children’s Hospital, said.

Alex Jahangir, MD, MMHC, of Vanderbilt University Medical Center, discusses innovative technologies to combat burnout and improve specialty care.

In this interview, Sarah Manes, Global Liver Institute, explores the unique challenges faced by LGBTQI+ individuals, particularly those with disabilities, in accessing and receiving appropriate liver care.

Findings from a post hoc analysis of 3 clinical trials support the switching to or initiation of pegcetacoplan to manage fatigue for patients with paroxysmal nocturnal hemoglobinuria (PNH) that is accompanied by mild to moderate anemia.

Findings from an Italian cohort suggest that nusinersen may benefit fatigue measures in patients with spinal muscular atrophy (SMA) type III; however, drawing definitive conclusions in this area remains difficult.

Katherine Baker, MD, MMHC, of Tennessee Oncology, highlights the need for physician-payer collaboration to tackle challenges and drive innovation in specialty care.

Fahad Tahir, MAS, MBA, FACHE, of Ascension St Thomas, discusses health system innovation and entrepreneurship, highlighting specialty care advancements and leadership strategies for fostering innovation.

Samyukta Mullangi, MD, MBA, of Tennessee Oncology and Thyme Care, discusses the future of specialty value-based care and how attendees can apply what they learned at the Institute for Value-Based Medicine event on August 22.

National data sets and registries are able to provide outcomes data and process measures that testify to quality of care being delivered, said Matthew Nielsen, MD, FACS, chair, Department of Urology, University of North Carolina School of Medicine.

By analyzing the surface proteome of a wide-ranging sample of acute myeloid leukemia (AML) specimens, researchers identified potential antigens and primitive cell markers representative of AML supgroups.

This second installment on the threat of forever chemicals examines the impactful policies brought about during the Biden-Harris administration that are set to play a role in the future manufacturing, use, and monitoring of these harmful substances.

Also known as coal workers’ pneumoconiosis, black lung disease (or miner’s lung) is typically the result of inhaling coal dust for many years that causes scarring in the lungs and makes breathing increasingly difficult. The prevalence of black lung has been on the rise in the US.

Improvements in multiplex immunofluorescence and spatial analysis have enabled a better understanding of the ways classical Hodgkin lymphoma evades the immune system.

The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy.